NASDAQ$TYRA
Tyra Biosciences Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Reported financial results for the quarter ended March 31, 2022, and highlighted recent corporate progress.
Tyra Biosciences reported a net loss of $14.8 million for the first quarter of 2022, with cash and cash equivalents totaling $292.5 million as of March 31, 2022. The company is on track to file INDs for TYRA-300 and TYRA-200 in 2022 and is progressing its pipeline.
- Net loss for Q1 2022 was $14.8 million, compared to $4.2 million for the same period in 2021.
- Research and development expense for Q1 2022 was $9.6 million, compared to $3.5 million for the same period in 2021.
- General and administrative expense for Q1 2022 was $5.2 million, compared to $0.7 million for the same period in 2021.
- Cash and cash equivalents totaled $292.5 million as of March 31, 2022.
Headline financials
Revenue & EPS history
Tyra Biosciences · Revenue · Quarterly
$0
Forward guidance
Tyra Biosciences anticipates submitting INDs for TYRA-300 in mid-2022 and TYRA-200 in the second half of 2022, while continuing to advance its pipeline.
Tailwinds
- Potential to develop next-generation targeted therapies that improve clinical outcomes.
- Expected IND submission timing for TYRA-300 and TYRA-200 remains on track.
- Planned advancement of the development pipeline, including expanding the nomination of clinical candidates from FGFR3-related skeletal dysplasia, RET and FGFR4 programs.
- Transitioning to a clinical-stage company.
- Focus on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer.
Headwinds
- Early stage of development efforts with no product candidates tested in clinical trials.
- Approach to discover and develop drugs based on the SNÅP platform is novel and unproven.
- Potential delays in the commencement, enrollment, and completion of preclinical studies and clinical trials.
- Dependence on third parties in connection with manufacturing, research and preclinical testing.
- Unexpected adverse side effects or inadequate efficacy of product candidates.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2022
+2.0%
Avg return
Earnings day
+3.0%
Avg return
5 days after
-0.8%
Avg return
30 days after
50%
9 / 18 earnings
Positive
+29.8%
Q3 2021
Best reaction
-11.5%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +1.5% | +7.7% | +21.8% | |
| Q3 2025 | +0.3% | +8.4% | +50.6% | |
| Q2 2025 | +0.4% | -4.3% | +17.0% | |
| Q1 2025 | -3.1% | -4.0% | +2.3% | |
| Q4 2024 | -0.8% | -10.5% | +3.9% | |
| Q3 2024 | -5.9% | -6.9% | -8.1% | |
| Q1 2024 | -3.8% | +3.1% | +9.7% | |
| Q4 2023 | +7.0% | +3.0% | -9.7% | |
| Q3 2023 | -6.3% | -8.1% | +2.5% | |
| Q2 2023 | +0.9% | +1.6% | -3.4% | |
| Q1 2023 | -3.3% | +7.0% | +13.1% | |
| Q4 2022 | -3.3% | +0.0% | -9.8% | |
| Q3 2022 | -7.1% | +12.9% | -3.1% | |
| Q2 2022 | +11.1% | +14.7% | -24.0% | |
| Q1 2022 | +0.1% | -5.9% | -17.8% | |
| Q4 2021 | -11.5% | -5.3% | -6.4% | |
| Q2 2021 | +29.8% | +20.3% | -26.6% | |
| Q3 2021 | +29.8% | +20.3% | -26.6% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro